TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04186936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Caplet with Loperamide HCl and Simethicone
Description: Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Caplet with Loperamide HCl and Simethicone
Description: Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
Study: NCT02102932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin/500 mg metformin FDC
Description: 12.5 mg empagliflozin/500 mg metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin/500 mg metformin FDC
Description: 5 mg empagliflozin/500 mg metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Description: 500 mg metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Description: 500 mg metformin
Study: NCT04186936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide HCl
Description: Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide HCl
Description: Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
Study: NCT01556880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Description: A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
Study: NCT03388515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSS11
Description: IV infusion for 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV infusion for 60 min.
Study: NCT01676727

Intervention type: DEVICE
Intervention: CoreValve aortic valve
Description: Implantation of CoreValve aortic valve via direct aortic approach
Study: NCT03200184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir and daclatasvir
Description: A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
Study: NCT00476359

Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir/r plus saquinavir
Description: lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
Study: NCT04091009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided
Study: NCT01919619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT03985111

Intervention type: DEVICE
Intervention: Central Venous Catheter
Description: Insertion of a central venous catheter insertion pre-operatively (electively)
Study: NCT04130984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-IO
Description: The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
Study: NCT00580970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
Study: NCT04056351

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Post-Operative (OP) Computer Tomography (CT)
Description: Post-OP CT of the treated shoulder

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires on patient activity and comorbidities
Description: * Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score

Intervention type: OTHER
Group type: OTHER
Intervention: Grip strength measurement
Description: Grip strength will be measured using a CE marked hydraulic hand dynamometer device.

Intervention type: OTHER
Group type: OTHER
Intervention: Non-invasive shoulder activity tracking usinig wearable sensors
Description: Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
Study: NCT03265301

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteroscopy
Description: Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteroscopy
Description: Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office hysteroscopy
Description: will be done in out patient clinic without anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional hysteroscopy
Description: will be done in operative room under general anesthesia
Study: NCT01808248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT04238715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 tablets orally.
Study: NCT03193567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEKT cell
Description: 3 cycles of HEKT cell treatment
Study: NCT02338622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AZD5363 BD
Study: NCT00689078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 0.12%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.2%
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study: NCT00773929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-593
Description: Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety
Study: NCT04284852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP inhibitor
Study: NCT01147640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101/ tazobactam and metronidazole
Description: CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem plus saline placebo
Description: meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
Study: NCT01826721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplant Medication Information Teaching Tool
Description: Online e-learning tool for post-transplant medication education.
Study: NCT01017471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited incision using PSU retractor
Description: carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
Study: NCT00658580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + etoposide
Description: Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin + ifosfamide + etoposide
Description: Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks
Study: NCT03425513

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis B serology
Description: A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
Study: NCT02869503

Intervention type: OTHER
Intervention: Data collection
Study: NCT02470416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD
Description: Cases and controls will have a standard VCE procedure at our institution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD
Description: Cases and controls will have a standard VCE procedure at our institution.
Study: NCT00835159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch
Description: Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
Study: NCT02215031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03221699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula with ZnO
Description: Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formula without ZnO
Description: Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
Study: NCT05428293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)
Description: Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)
Description: Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)
Description: Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
Study: NCT02996695

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01629342

Intervention type: BEHAVIORAL
Intervention: Standardized activities
Description: All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)
Study: NCT01808248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04445701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176
Description: Humanized monoclonal antibody (mAb) targeting CD47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Dex
Description: Humanized mAb targeting CD47 plus dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Dex + Bort
Description: Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
Study: NCT01745081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% mannitol bolus administration
Study: NCT03701399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troriluzole
Description: 200 mg by mouth
Study: NCT03480061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride Group
Description: Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
Study: NCT03157635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.
Study: NCT03701399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 200 mg by mouth
Study: NCT02738632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine+Hydrochlorothiazide
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Hydrochlorothiazide
Study: NCT04040244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Collection
Description: Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples collected simultaneously with routine standard of care blood draws.
Study: NCT03564028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy conservation technique
Description: During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.

Intervention type: OTHER
Group type: OTHER
Intervention: control session
Description: Patients will realize one session of stair climbing at their own pace
Study: NCT00437320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Cream 160 mg/g
Description: Participants were treated with topical administration of Metvix cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Cream 160 mg/g
Description: Participants were treated with topical administration of Metvix cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Cream 160 mg/g
Description: Participants were treated with topical administration of Metvix cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Vehicle Group
Description: Participants were treated with topical administration of Metvix Vehicle cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Vehicle Group
Description: Participants were treated with topical administration of Metvix Vehicle cream.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Vehicle Group
Description: Participants were treated with topical administration of Metvix Vehicle cream.
Study: NCT02987842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruScan Neurofeedback
Description: Neurofeedback and quantitative EEG system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TruScan Neurofeedback
Description: Neurofeedback and quantitative EEG system
Study: NCT01938573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT01745081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 3% bolus administration
Study: NCT00519103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Study: NCT01324544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine IV
Description: Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
Study: NCT03854409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.
Study: NCT00003387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy